Mogamulizumab-kpkc is use in adult patients with either of two types of cutaneous T-cell lymphoma
Trade name Poteligeo.
Treatment option for patients with relapsed or refractory mycosis fungoides (MF) and is the first drug to be approved for use in the treatment of Sézary syndrome (SS).
Mycosis fungoides and Sézary syndrome are the most common subtypes of cutaneous T-cell lymphomas.
The drug has been approved in Japan for another rare disease, adult T-cell leukemia lymphoma.
In a large phase 3 MAVORIC trial comparing mogamulizumab with vorinostat (Zolinza) which is an FDA-approved standard-of-care treatment for patients: The results showed that mogamulizumab demonstrated significantly superior progression-free survival (PFS) with a median of 7.6 months vs 3.1 months with vorinostat.
The confirmed overall response rate was 28% with mogamulizumab vs 5% with vorinostat.
The most common adverse reactions were rash, including drug eruption (35%), infusion reaction (33%), fatigue (31%), diarrhea (28%), drug eruption (24%), upper respiratory tract infection (22%), musculoskeletal pain (22%), skin infection (19%), pyrexia (17%), edema (16%), nausea (16%), headache (14%), thrombocytopenia (14%), constipation (13%), anemia (12%), mucositis (12%), cough (11%), and hypertension (10%).